Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...

Danish clinical-stage AI-based vaccine developer Evaxion Biotech (Nasdaq: EVAX) has entered into an option and license ...

US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated ...

Pfizer has withdrawn Oxbryta (voxelotor), a sickle cell disease treatment, from global markets due to new clinical data ...

Evotec has entered a partnership with Novo Nordisk to develop next-generation off-the-shelf cell therapy technologies. Novo ...

Merck's Phase III KEYFORM-007 trial, testing a combination of favezelimab and Keytruda, failed to meet its primary endpoint ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja (leniolisib) ...

Amgen's shares fell over 5% after updates on its Phase III immunology drug, rocatinlimab, raised investor concerns. While the ...

The US Food and Drug Administration (FDA) has approved a new indication for AstraZeneca’s Tagrisso (osimertinib), which is ...

Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara ...

LEO Pharma has presented late-breaking data on the DELTA FORCE trial for Anzupgo (delgocitinib) cream as a potential ...